139 related articles for article (PubMed ID: 31792355)
41. The central fibroblast growth factor receptor/beta klotho system: Comprehensive mapping in Mus musculus and comparisons to nonhuman primate and human samples using an automated in situ hybridization platform.
Hultman K; Scarlett JM; Baquero AF; Cornea A; Zhang Y; Salinas CBG; Brown J; Morton GJ; Whalen EJ; Grove KL; Koegler FH; Schwartz MW; Mercer AJ
J Comp Neurol; 2019 Aug; 527(12):2069-2085. PubMed ID: 30809795
[TBL] [Abstract][Full Text] [Related]
42. Antibody-mediated activation of FGFR1 induces FGF23 production and hypophosphatemia.
Wu AL; Feng B; Chen MZ; Kolumam G; Zavala-Solorio J; Wyatt SK; Gandham VD; Carano RA; Sonoda J
PLoS One; 2013; 8(2):e57322. PubMed ID: 23451204
[TBL] [Abstract][Full Text] [Related]
43. FGF23 Regulates Bone Mineralization in a 1,25(OH)2 D3 and Klotho-Independent Manner.
Murali SK; Roschger P; Zeitz U; Klaushofer K; Andrukhova O; Erben RG
J Bone Miner Res; 2016 Jan; 31(1):129-42. PubMed ID: 26235988
[TBL] [Abstract][Full Text] [Related]
44. Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation.
Goetz R; Nakada Y; Hu MC; Kurosu H; Wang L; Nakatani T; Shi M; Eliseenkova AV; Razzaque MS; Moe OW; Kuro-o M; Mohammadi M
Proc Natl Acad Sci U S A; 2010 Jan; 107(1):407-12. PubMed ID: 19966287
[TBL] [Abstract][Full Text] [Related]
45. Expression of FGF23/KLOTHO system in human vascular tissue.
Donate-Correa J; Mora-Fernández C; Martínez-Sanz R; Muros-de-Fuentes M; Pérez H; Meneses-Pérez B; Cazaña-Pérez V; Navarro-González JF
Int J Cardiol; 2013 Apr; 165(1):179-83. PubMed ID: 21945708
[TBL] [Abstract][Full Text] [Related]
46. TIO Associated with Hyperparathyroidism: A Rarity, a Rule, or a Novel HPT-PMT Syndrome-A Case Study with Literature Review.
Salim M; Behairy MS; Barengolts E
Case Rep Endocrinol; 2021; 2021():5172131. PubMed ID: 34354845
[TBL] [Abstract][Full Text] [Related]
47. Identification of a novel HOOK3-FGFR1 fusion gene involved in activation of the NF-kappaB pathway.
Zhang X; Wang F; Yan F; Huang D; Wang H; Gao B; Gao Y; Hou Z; Lou J; Li W; Yan J
Cancer Cell Int; 2022 Jan; 22(1):40. PubMed ID: 35081975
[TBL] [Abstract][Full Text] [Related]
48. [Hormonal regulation of phosphate balance].
Tanaka H; Fukagawa M
Clin Calcium; 2012 Oct; 22(10):1477-85. PubMed ID: 23023626
[TBL] [Abstract][Full Text] [Related]
49. Identification of Small-Molecule Inhibitors of Fibroblast Growth Factor 23 Signaling via In Silico Hot Spot Prediction and Molecular Docking to α-Klotho.
Liu SH; Xiao Z; Mishra SK; Mitchell JC; Smith JC; Quarles LD; Petridis L
J Chem Inf Model; 2022 Aug; 62(15):3627-3637. PubMed ID: 35868851
[TBL] [Abstract][Full Text] [Related]
50. Persistent phosphaturic mesenchymal tumor causing tumor-induced osteomalacia treated with image-guided ablation.
Horng JC; Van Eperen E; Tutton S; Singh R; Shaker JL; Wooldridge AN
Osteoporos Int; 2021 Sep; 32(9):1895-1898. PubMed ID: 33655402
[TBL] [Abstract][Full Text] [Related]
51. Phosphaturic mesenchymal tumor, nonphosphaturic variant, causing fatal pulmonary metastasis.
Uchihashi K; Nishijima-Matsunobu A; Matsuyama A; Yamasaki F; Tanabe T; Uemura T; Aragane N; Yakushiji M; Yamamoto M; Aoki S; Toda S
Hum Pathol; 2013 Nov; 44(11):2614-8. PubMed ID: 23954138
[TBL] [Abstract][Full Text] [Related]
52. FGFR inhibitors: Effects on cancer cells, tumor microenvironment and whole-body homeostasis (Review).
Katoh M
Int J Mol Med; 2016 Jul; 38(1):3-15. PubMed ID: 27245147
[TBL] [Abstract][Full Text] [Related]
53. Fgf23 and parathyroid hormone signaling interact in kidney and bone.
Andrukhova O; Streicher C; Zeitz U; Erben RG
Mol Cell Endocrinol; 2016 Nov; 436():224-39. PubMed ID: 27498418
[TBL] [Abstract][Full Text] [Related]
54. Diagnostic Utility of a Custom 34-Gene Anchored Multiplex PCR-Based Next-Generation Sequencing Fusion Panel for the Diagnosis of Bone and Soft Tissue Neoplasms With Identification of Novel USP6 Fusion Partners in Aneurysmal Bone Cysts.
Dermawan JK; Cheng YW; Tu ZJ; Meyer A; Habeeb O; Zou Y; Goldblum JR; Billings SD; Kilpatrick SE; Reith JD; Shurtleff SA; Farkas DH; Rubin BP; Azzato EM
Arch Pathol Lab Med; 2021 Jul; 145(7):851-863. PubMed ID: 33147323
[TBL] [Abstract][Full Text] [Related]
55. Immunohistochemical and molecular detection of the expression of FGF23 in phosphaturic mesenchymal tumors including the non-phosphaturic variant.
Shiba E; Matsuyama A; Shibuya R; Yabuki K; Harada H; Nakamoto M; Kasai T; Hisaoka M
Diagn Pathol; 2016 Mar; 11():26. PubMed ID: 26956379
[TBL] [Abstract][Full Text] [Related]
56. Phosphaturic Mesenchymal Tumor Along the Hallux side Inducing a Chronic non-Healing Wound: A Case Report with Literature Review.
Sun X; Ni P; Xie T; Wu S
Int J Low Extrem Wounds; 2023 Dec; 22(4):779-787. PubMed ID: 35043721
[TBL] [Abstract][Full Text] [Related]
57. Phosphaturic mesenchymal tumor and related wound problem.
Xiao X; Sun X; Ni P; Huang Y; Xie T
Medicine (Baltimore); 2018 Oct; 97(40):e12507. PubMed ID: 30290606
[TBL] [Abstract][Full Text] [Related]
58. [Clinical and immunohistopathologic study of phosphaturic mesenchymal tumor].
Li DM; Wu HW; Li JD; Xia WB; Jiang Y; Zhong DR
Zhonghua Bing Li Xue Za Zhi; 2018 Jun; 47(6):427-431. PubMed ID: 29886586
[No Abstract] [Full Text] [Related]
59. LncRNA-SNHG29 inhibits vascular smooth muscle cell calcification by downregulating miR-200b-3p to activate the α-Klotho/FGFR1/FGF23 axis.
Huang C; Zhan JF; Chen YX; Xu CY; Chen Y
Cytokine; 2020 Dec; 136():155243. PubMed ID: 32818704
[TBL] [Abstract][Full Text] [Related]
60. Phosphaturic mesenchymal tumors show positive staining for somatostatin receptor 2A (SSTR2A).
Houang M; Clarkson A; Sioson L; Elston MS; Clifton-Bligh RJ; Dray M; Ranchere-Vince D; Decouvelaere AV; de la Fouchardiere A; Gill AJ
Hum Pathol; 2013 Dec; 44(12):2711-8. PubMed ID: 24060005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
